We compared 262 patients [median age: 66 years (15–88); 122 M, 140 F] with 262 age- and sex-comparable healthy subjects.
Circulating concentrations of Lp(a) were found to be significantly different in patients when compared to healthy subjects [189 (60–1898) mg/L vs. 119.5 (6–1216) mg/L; p < 0.0001, respectively]. No significant differences were observed relating to the different types of occlusion (central or branch occlusion). In order to investigate the possible association between high Lp(a) levels and the disease we performed a logistic regression analysis. In the univariate analysis, Lp(a) levels > 300 mg/L were found to be associated with an increased risk of RVO (OR: 2.39, 95 % CI 1.39–3.59; p < 0.0001). Following this, three models of multivariate analysis were performed, firstly by adjusting for age, gender, and traditional cardiovascular risk factors, secondly for triglycerides and thirdly for homocysteine levels. In all the models, Lp(a) levels > 300 mg/L confirmed their role as a risk factor for RVO [first model, OR: 2.15 (95 % CI 1.39–3.32), p = 0.0001; second model, OR: 3.11 (95 % CI 1.77–5.62), p < 0.00001; third model, OR: 3.48 (95 % CI 1.88–6.43), p < 0.00001].
This study reports that, in a large population of RVO patients, high Lp(a) concentrations are significantly related to RVO, independent from other traditional and emerging risk factors, suggesting that they may play a role in its pathogenesis.